Literature DB >> 23896309

Combinations of oxazepam and metyrapone attenuate cocaine and methamphetamine cue reactivity.

Courtney M Keller1, Elyse M Cornett, Glenn F Guerin, Nicholas E Goeders.   

Abstract

BACKGROUND: We have previously reported that combining low doses of oxazepam and metyrapone (OX/MET) reduces intravenous cocaine self-administration without affecting stress-hormone levels. We hypothesized that the combination of OX/MET would also inhibit the reinstatement of cocaine or methamphetamine seeking induced by the presentation of a conditioned reinforcer and that stress hormone levels would not be influenced by this treatment.
METHODS: Male rats were implanted with jugular catheters and trained to self-administer cocaine or methamphetamine during daily 2-h sessions. During training, cocaine or methamphetamine delivery was paired with the presentation of a tone and the illumination of a house light. Following stable self-administration, rats were placed into forced abstinence. During cue-reactivity testing, rats were placed back into the operant chambers and responding only resulted in the presentation of the conditioned reinforcer; no cocaine or methamphetamine was delivered. Blood was collected on the last day of self-administration and on the day of cue-reactivity testing (either 15-min or 2-h session) to assess plasma corticosterone.
RESULTS: The response-contingent presentation of the conditioned reinforcer reliably maintained cocaine or methamphetamine seeking following vehicle pretreatment. Pretreatment with OX/MET resulted in a dose-related attenuation of both cocaine and methamphetamine seeking. Corticosterone levels were significantly different at the end of the 15-min session, but not following the 2-h session.
CONCLUSION: These data suggest that OX/MET may be useful in blocking the ability of environmental cues to stimulate both cocaine and methamphetamine seeking and that this effect is not entirely dependent on stress hormone levels.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cocaine; Corticosterone; Cue reactivity; Methamphetamine; Metyrapone; Oxazepam

Mesh:

Substances:

Year:  2013        PMID: 23896309     DOI: 10.1016/j.drugalcdep.2013.06.025

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  6 in total

1.  Effects of inhibitory GABA-active neurosteroids on cocaine seeking and cocaine taking in rats.

Authors:  Christopher D Schmoutz; Scott P Runyon; Nicholas E Goeders
Journal:  Psychopharmacology (Berl)       Date:  2014-01-08       Impact factor: 4.530

Review 2.  Neuroinflammatory Response in Reward-Associated Psychostimulants and Opioids: A Review.

Authors:  Saeideh Karimi-Haghighi; Sara Chavoshinezhad; Roghayeh Mozafari; Farshid Noorbakhsh; Afshin Borhani-Haghighi; Abbas Haghparast
Journal:  Cell Mol Neurobiol       Date:  2022-04-23       Impact factor: 5.046

3.  Differential interactions engendered by benzodiazepine and neuroactive steroid combinations on schedule-controlled responding in rats.

Authors:  Barak W Gunter; Donna M Platt; James K Rowlett
Journal:  Pharmacol Biochem Behav       Date:  2015-08-06       Impact factor: 3.533

4.  Role of Hypothalamic-Pituitary-Adrenal axis and corticotropin-releasing factor stress system on cue-induced relapse to alcohol seeking.

Authors:  Fernanda L Galesi; Lydia O Ayanwuyi; Miriam Garcia Mijares; Andrea Cippitelli; Nazzareno Cannella; Roberto Ciccocioppo; Massimo Ubaldi
Journal:  Eur J Pharmacol       Date:  2016-06-15       Impact factor: 4.432

Review 5.  Methamphetamine and the hypothalamic-pituitary-adrenal axis.

Authors:  Damian G Zuloaga; Jason S Jacobskind; Jason S Jacosbskind; Jacob Raber
Journal:  Front Neurosci       Date:  2015-05-27       Impact factor: 4.677

Review 6.  Consideration of sex as a biological variable in the translation of pharmacotherapy for stress-associated drug seeking.

Authors:  Erin L Martin; Elizabeth M Doncheck; Carmela M Reichel; Aimee L McRae-Clark
Journal:  Neurobiol Stress       Date:  2021-07-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.